CYP19A1 and breast cancer: Third-generation aromatase inhibitors (AIs) are currently the most effective treatment and have been shown to be superior to tamoxifen for hormone receptor positive, postmenopausal breast cancer as aromatase catalyses the conversion of circulating androgenic precursors to estrogens [46-48].